Ischemic Priapism — ED Management

Key Points

• A painful rigid erection lasting about 4 hours is an acute ischemic emergency.
• Classify priapism before treatment because ischemic and nonischemic forms require different management.
• Do not delay aspiration and phenylephrine while pursuing the underlying cause.
• Intracavernosal phenylephrine plus corporal aspiration and irrigation is first-line therapy.
• Monitor blood pressure and pulse during repeated phenylephrine administration.
• Failure of first-line therapy requires urgent urologic surgical escalation.
• Sickle cell disease requires the same immediate local decompression strategy; systemic sickle treatment is concurrent, not a substitute.
• The risk of permanent erectile dysfunction rises with duration of ischemia.

Algorithm

1. Confirm duration, pain, rigidity, medication and drug exposures, trauma, hematologic disease, and prior episodes.
2. Examine whether the corpora are fully rigid and painful and whether the glans remains relatively soft.
3. If the subtype is uncertain, obtain cavernosal blood gas and/or penile Doppler without delaying treatment of an obvious ischemic episode.
4. Provide local anesthesia, aspirate corporal blood, and irrigate as appropriate.
5. Administer intracavernosal phenylephrine in protocol-based repeated doses with cardiovascular monitoring.
6. Reassess detumescence and pain after each treatment cycle.
7. If detumescence is not achieved promptly, proceed to urologic shunt or other surgical management.
8. After resolution, investigate the cause and arrange erectile-function and recurrence follow-up.

Clinical Synopsis & Reasoning

Priapism must first be classified as ischemic, nonischemic, or recurrent ischemic because management differs. Ischemic priapism is typically painful, with rigid corpora cavernosa and a relatively soft glans. Nonischemic priapism usually follows perineal trauma, is less painful, and produces a partially rigid erection because arterial inflow remains high. Recurrent ischemic priapism consists of repeated painful episodes, often in sickle cell disease or other predispositions, and an episode lasting approximately 4 hours should be treated as an acute ischemic event.

History should identify duration, pain severity, previous episodes, erectile medications or injections, trazodone or antipsychotic use, cocaine or other drugs, hematologic disease, trauma, malignancy, and neurologic disease. Ischemic injury progresses with time. Corporal smooth-muscle damage and fibrosis can lead to permanent erectile dysfunction, so treatment should not be deferred while waiting for an exhaustive etiologic workup.

When the subtype is uncertain, aspirated cavernosal blood in ischemic priapism is typically dark and hypoxic with acidosis and hypercapnia. Penile Doppler can demonstrate little or no cavernosal arterial flow. Blood tests are targeted to the suspected cause and can include CBC, reticulocyte count, sickle cell testing when status is unknown, and toxicology testing when useful. The emergency procedure remains the priority.

Treatment Strategy & Disposition

Provide penile or local anesthesia when needed, then aspirate blood from the corpora cavernosa and irrigate with normal saline. Intracavernosal phenylephrine is the preferred sympathomimetic because of its alpha-1 selectivity. The AUA/SMSNA guideline describes phenylephrine 100 to 500 micrograms in 1 mL normal saline injected into the corpora every 5 minutes, with dosing adjusted to patient factors and response. Monitor blood pressure and heart rate, especially in patients with cardiovascular disease or those receiving repeated doses.

Aspiration and phenylephrine can be performed in sequence or together until detumescence is achieved or escalation is required. If the erection persists despite first-line therapy, urgent urologic surgery is indicated, typically beginning with a distal shunt procedure, with additional procedures determined by duration, tissue viability, and specialist judgment. Prolonged episodes have a high risk of erectile dysfunction even after successful detumescence.

Sickle cell disease does not change the need for immediate local treatment. Hydration, oxygen for hypoxemia, analgesia, and management of the underlying sickle complication can occur concurrently, but exchange transfusion should not delay aspiration and phenylephrine. Nonischemic priapism generally does not require emergency aspiration or phenylephrine and is managed with urologic assessment, observation, or selective arterial embolization when persistent and bothersome.

Epidemiology / Risk Factors

• Common causes include intracavernosal erectile medications, trazodone, antipsychotics, hematologic disease, malignancy, and recreational drugs, although many cases are idiopathic.
• Sickle cell disease is an important cause of recurrent ischemic priapism and can affect children, adolescents, and adults.
• Nonischemic priapism is usually associated with blunt perineal or penile trauma and arteriocavernosal fistula formation.
• Repeated ischemic episodes can produce cumulative erectile tissue injury even when each episode resolves.
• Drug-related cases should prompt medication review and prevention planning after the emergency is controlled.

Investigations

Phenylephrine Dosing (Adult)

Pharmacology

Prognosis / Complications

• Shorter ischemic episodes treated promptly have the best chance of preserving erectile function.
• Prolonged priapism causes corporal fibrosis and can lead to permanent erectile dysfunction despite successful detumescence.
• Recurrence is common in patients with sickle cell disease or medication-related predisposition unless the underlying driver is addressed.
• Surgical shunting can relieve ischemia but does not reverse tissue injury that has already occurred.
• Long-term urologic follow-up is important after severe or recurrent episodes.

Patient Education / Counseling

• Tell patients to seek emergency care for a painful erection approaching 4 hours rather than waiting for spontaneous resolution.
• Review prescription medications, injection technique, recreational substances, and hematologic disease as possible contributors.
• Patients using intracavernosal erectile therapy should receive explicit instructions on dosing and when to seek help.
• Discuss the possibility of erectile dysfunction after a prolonged episode and arrange urology follow-up rather than waiting for symptoms to become chronic.
• For recurrent priapism, prevention strategies should be developed with urology and hematology when sickle cell disease is present.
• Patients should not attempt unapproved home drainage or repeated unmonitored sympathomimetic dosing.

Notes

Acute ischemic priapism should be approached like a compartment syndrome of the corpora. The treatment target is rapid restoration of venous outflow and oxygenated blood flow, not simply pain reduction.

The AUA/SMSNA guideline emphasizes early intervention and does not recommend delaying definitive local therapy for systemic measures in sickle cell disease.

References

1. AUA/SMSNA Diagnosis and Management of Priapism Guideline — Link
2. AUA Acute Ischemic Priapism Guideline — Link